NCT02876068: Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies |
|
|
| Active, not recruiting | 1 | 19 | US | Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib, ARRY-142886, AZD6244, MEK Inhibitor AZD6244 | Mayo Clinic, National Cancer Institute (NCI) | Solid Neoplasm, Stage IV Skin Melanoma | 06/16 | | | |
NCT01364051: Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies |
|
|
| Active, not recruiting | 1 | 19 | US | Cediranib, AZ-D2171, AZD2171, Cediranib Maleate, AZD2171 Maleate, Recentin, Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib, ARRY-142886, AZD6244, MEK Inhibitor AZD6244, Selumetinib Sulfate, AZD-6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulphate, Koselugo, Selumetinib Sulphate | National Cancer Institute (NCI) | Metastatic Melanoma, Refractory Malignant Solid Neoplasm, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm | 06/19 | 03/25 | | |
